Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib versus crizotinib in treatment-naive ALK-positive advanced non-small cell lung cancer
CTR20150592Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of alectinib, crizotinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Nov 2015; status: completed.
02
Drugs
alectinibcrizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20150592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150592.